Analyst Price Target is GBX 0
This price target is based on 0 analysts offering 12 month price targets for Mediclinic International in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a NaN upside from the last price of GBX 0.
Current Consensus is
N/A
The current consensus among 0 investment analysts is to n/a stock in Mediclinic International. This rating has held steady since August 2023, when it changed from a Hold consensus rating.
Mediclinic International plc, together with its subsidiaries, operates private hospitals. The company offers specialist-orientated and multidisciplinary healthcare services under the Mediclinic and Hirslanden brand names. It operates 74 hospitals, 20 day case clinics, 22 outpatient clinics, 5 subacute hospitals, 2 mental health facilities, and 453 theatres with approximately 11,538 inpatient beds in Switzerland, South Africa, Namibia, the Middle East, and the United Kingdom. The company also provides treasury, hospital equipment and procurement, emergency medical, management, food and catering, healthcare management, and debt collection and related services; manages healthcare staff; and owns and manages properties. In addition, it engages in the intellectual property holding and medical store/procurement businesses. The company was founded in 1983 and is based in Stellenbosch, South Africa.
Read More
